Craft
  • Home
  •  / Talaris Therapeutics
Talaris Therapeutics

Talaris Therapeutics

Market Capitalization

$134.3 M

2022-09-19

Talaris Therapeutics Summary

Company summary

Overview
Talaris Therapeutics is a cell therapy company developing an method of allogeneic hematopoietic stem cell transplantation. Its Facilitated Allo-HSCT Therapy can prevent organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines, also known as chronic immunosuppression. The company aims to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders.
Type
Public
Founded
2002
HQ
Wellesley, MA, US | view all locations
Website
https://talaristx.com
Cybersecurity rating
Sectors

Key people

  • Scott Requadt

    Scott Requadt, Chief Executive Officer

  • Suzanne Ildstad

    Suzanne Ildstad, Founder and Chief Scientific Officer

  • Andrew Farnsworth

    Andrew Farnsworth, Chief Human Resources Officer

  • Nancy Krieger

    Nancy Krieger, Chief Medical Officer

LocationsView all

5 locations detected

  • Wellesley, MA HQ

    United States

    93 Worcester Street Suite 120

  • Houston, TX

    United States

    9940 W Sam Houston Pkwy S #300

  • Louisville, KY

    United States

    201 East Jefferson Street, Suite 110B

  • Louisville, KY

    United States

    570 S. Preston St.

  • Louisville, KY

    United States

    The Nucleus Building, 300 E Market St #350

Talaris Therapeutics Financials

Summary financials

Footer menu